Plasma androgens after a single oral dose of testosterone undecanoate

GILLIAN GEERE, JENNIFER JONES, SHELIA M Atherden, and D B Grant

The Institute of Child Health, London

SUMMARY Total plasma androgens (PA) were measured in 9 hypogonadal males aged between 13 and 21½ years after a single oral dose of testosterone undecanoate (TU). With the exception of one patient, all showed a rise in PA with peak values between 7.7 and 38.0 nmol/l at 2 to 7 hours. A further patient aged 15-7 years who was given an 80-mg dose had a peak PA level of 71.2 nmol/l. In all patients PA returned to basal levels at 24 hours. In 4 patients plasma testosterone and dihydrotestosterone were measured, both rose after oral TU, and relatively high plasma dihydrotestosterone values were obtained. While these results indicate that TU is effective in young people, the very high peak androgen levels found in several of them after 40 mg TU suggest that this dose may be excessive in patients in whom growth is not complete.

Treatment with androgen is generally necessary in boys with hypogonadism to produce normal secondary sexual development at adolescence. While satisfactory results can be obtained with fairly low doses of testosterone esters given by injection every 4 to 6 weeks, an effective oral preparation would be more convenient. Testosterone undecanoate (TU) (Organon Laboratories), a lipid-soluble preparation which is absorbed into the intestinal lymphatics and which does not have the hepatotoxic effects of 17α-methyl-testosterone, has been used with success in hypogonadal men.1,2 However, there is no information on the appropriate dose for younger people. The plasma androgen levels after a single dose of testosterone undecanoate in 10 young hypogonadal males are described.

Subjects and methods

Ten males aged between 13 and 21½ years were studied. Clinical details are given in Table 1. In 9 of them previous surgical exploration for undescended testes had shown bilateral remnants of vas with either no recognisable testes (Cases 1–7) or very small hypoplastic testes (Cases 9 and 10). Surgical exploration had not been carried out in one boy with undescended testes associated with gonadotrophin deficiency and hyposmia (Kallman's syndrome). Nine of them had already been treated with a depot preparation of testosterone enanthate (100–250 mg every 4 to 8 weeks) for 1 to 3.4 years. These patients, none of whom had shown spontaneous pubertal development before treatment, were studied 4 to 6 weeks after their last injections.

Table 1  Clinical details of the 10 patients given testosterone undecanoate. Basal values for serum LH and FSH are also given.

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (years)</th>
<th>Height (cm)</th>
<th>Weight (kg)</th>
<th>Diagnosis</th>
<th>Serum LH (IU/l)</th>
<th>Serum FSH (IU/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>13–9</td>
<td>158</td>
<td>41</td>
<td>Anorchia</td>
<td>15</td>
<td>&gt;40</td>
</tr>
<tr>
<td>2</td>
<td>14–5</td>
<td>157</td>
<td>57</td>
<td>Anorchia</td>
<td>10</td>
<td>&gt;40</td>
</tr>
<tr>
<td>3</td>
<td>14–5</td>
<td>153</td>
<td>39</td>
<td>Anorchia</td>
<td>5</td>
<td>&gt;40</td>
</tr>
<tr>
<td>4</td>
<td>15–7</td>
<td>165</td>
<td>48</td>
<td>Anorchia</td>
<td>23</td>
<td>&gt;40</td>
</tr>
<tr>
<td>5</td>
<td>16–7</td>
<td>176</td>
<td>67</td>
<td>Anorchia</td>
<td>13</td>
<td>&gt;40</td>
</tr>
<tr>
<td>6</td>
<td>18–5</td>
<td>191</td>
<td>75</td>
<td>Anorchia</td>
<td>9</td>
<td>&gt;40</td>
</tr>
<tr>
<td>7</td>
<td>21–5</td>
<td>182</td>
<td>64</td>
<td>Anorchia</td>
<td>11</td>
<td>&gt;40</td>
</tr>
<tr>
<td>8*</td>
<td>13–0</td>
<td>144</td>
<td>39</td>
<td>Gonadotrophin deficiency</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>9</td>
<td>16–6</td>
<td>178</td>
<td>65</td>
<td>Gonadotrophin deficiency</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>10</td>
<td>20–0</td>
<td>161</td>
<td>62</td>
<td>Gonadotrophin deficiency</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
</tbody>
</table>

*No previous treatment with testosterone.
single dose of testosterone undecanoate was given orally between 0930 and 1030 hours after a normal breakfast. Further blood samples were taken 2, 4, 7, and 24 hours later. Nine patients were given 40 mg TU and a dose of 80 mg was given to one patient (Case 4).

Total plasma androgens (PA) were measured by radioimmunoassay in all the samples after extraction with ether:hexane (4:1). In 4 patients plasma testosterone (T) and dihydrotestosterone (DHT) were assayed separately after chromatography of the plasma extract on celite microcolumns and elution with 10% ethyl acetate in iso-octane (DHT fraction) and 20% ethyl acetate in iso-octane (T fraction).\(^3\)–\(^4\) In general the PA values were lower than the combined values for T and DHT (PA 0·78 (T + DHT) + 0·8; r 0·99). This can probably be explained by the lower affinity of the antiserum for DHT, resulting in an underestimate of the DHT contribution to the PA results.

Using these assays the mean (± 1 SD) plasma androgen levels in 8 healthy adult men were as follows: PA 16.3 ± 3.1 nmol/l; T 13.1 ± 3.3 nmol/l; DHT 2.8 ± 0.9 nmol/l. The average DHT:T ratio was 0·28.

Luteinising hormone (LH) and follicle-stimulating hormone (FSH) were estimated in serum by double antibody radioimmunoassay using the MRC standards 68/40 and 69/104 respectively.

Results

Total androgens (Table 2). There was a rise in PA after administration of TU in all but one patient (Case 6). The timing of the peak value varied but in all patients the PA levels had returned to basal levels 24 hours later. There was considerable variation, from 7·7 to 38·0 nmol/l, in the peak concentration after 40 mg TU. The only patient to be given 80 mg dose (Case 4) had a very high PA level, 71·2 nmol/l at 2 hours, but this was not sustained.

Testosterone and dihydrotestosterone. In the 4 patients investigated (Cases 2, 4, 7, and 10), both T and DHT levels increased after administration of TU (Table 3). The DHT:T ratios varied between 0·4 and 3·1, and were much higher than the ratios found in normal men. There was no evidence of any consistent change in the DHT:T ratio at different times after TU administration.

LH and FSH. The basal LH and FSH values are given in Table 1. Three patients had very low values, indicating the presence of hypogonadotrophic hypogonadism. The remainder had grossly raised
plasma levels were much higher than would be expected in normal men. There was also considerable variation in the timing of the peak androgen level but in all but one a rise was apparent 2 hours later, and by 24 hours the plasma levels had returned to basal values.

In the 4 patients in whom both T and DHT were measured, the peak plasma DHT values were very much higher than would be expected in normal men, and similar results were reported by Hirschhäuser et al.1

We expected that plasma LH would be suppressed after testosterone undecanoate administration, but no consistent changes were found after a 40-mg dose. This may be due to the relatively brief increase in plasma T in our study, as Franchimont et al.5 found progressive suppression of plasma LH during continued administration of testosterone undecanoate to hypogonadal men.

While these results do not permit any conclusions on the place of testosterone undecanoate in the long-term management of adolescent boys with hypogonadism, they suggest that a 40-mg dose may be excessive, particularly in the early stages of treatment. Very high plasma androgen levels were obtained with this dose and it is possible that these could lead to disproportionately rapid bone maturation. The short-lived effect of a single dose may not be a disadvantage as T secretion is episodic in adolescent boys5 and the metabolic effect may persist as a result of tissue binding. The high plasma DHT levels also call for caution when treating young patients with this preparation. There is some evidence that the metabolic effects of T and DHT differ in different tissues, for example muscle,7 and the relative importance of DHT in adolescent growth and bone maturation is still not clear.

We thank Mr D R Thomas, Organon Laboratories Ltd for the supply of testosterone undecanoate.

J J is supported by a grant from the MRC and G G by grants from Organon Laboratories, the Smith, Kline, and French Foundation, and the Joint Research Board of The Hospital for Sick Children and Institute of Child Health.

References


Correspondence to Dr D B Grant, The Hospital for Sick Children, Great Ormond Street, London WC1N 3JH.

Received 3 April 1979